Observational studyJournal of ovarian research2026

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.

Susheel Kumar Yeshala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.